414,035 Shares in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Bought by MPM Bioimpact LLC

MPM Bioimpact LLC bought a new position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 414,035 shares of the company's stock, valued at approximately $10,641,000. MPM Bioimpact LLC owned 0.48% of IDEAYA Biosciences at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. R Squared Ltd acquired a new position in shares of IDEAYA Biosciences in the fourth quarter worth about $35,000. Daiwa Securities Group Inc. grew its holdings in IDEAYA Biosciences by 44.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company's stock worth $72,000 after buying an additional 853 shares in the last quarter. KBC Group NV grew its holdings in IDEAYA Biosciences by 84.6% in the 4th quarter. KBC Group NV now owns 4,197 shares of the company's stock worth $108,000 after buying an additional 1,923 shares in the last quarter. Cibc World Markets Corp bought a new position in IDEAYA Biosciences in the 4th quarter worth approximately $203,000. Finally, Mariner LLC grew its holdings in IDEAYA Biosciences by 9.8% in the 4th quarter. Mariner LLC now owns 9,775 shares of the company's stock worth $251,000 after buying an additional 869 shares in the last quarter. Hedge funds and other institutional investors own 98.29% of the company's stock.

Analyst Ratings Changes

Separately, Stephens reaffirmed an "overweight" rating and set a $50.00 price target on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Two equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $54.27.

IDEAYA Biosciences Price Performance

Shares of IDYA traded up $0.06 during trading hours on Monday, hitting $17.88. 350,348 shares of the company were exchanged, compared to its average volume of 1,151,355. The company has a market capitalization of $1.57 billion, a PE ratio of -5.42 and a beta of 0.26. The firm has a fifty day simple moving average of $17.64 and a 200-day simple moving average of $22.18. IDEAYA Biosciences, Inc. has a one year low of $13.45 and a one year high of $44.42.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same quarter in the prior year, the firm posted ($0.53) earnings per share. Sell-side analysts expect that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.